Posted on September 11, 20259/11/25
The Most-Favored-Nation Model: Global Benchmark or Global Risk?
Posted on September 10, 20259/10/25
The Evolution of the 340B Rebate Model: Maintaining Patient Access while Minimizing Duplicate Discounts
Posted on September 10, 20259/10/25
2026 CMS Proposed Rule: BFSF Changes and Potential Risks for Pharma Manufacturers
Posted on September 10, 20259/10/25
Navigating OBBBA: Why a Strong GP Team is Essential for Pharma Compliance
Posted on July 15, 20257/15/25
Where Process Meets Profit: How Strategic Order to Cash Drives Real Revenue Outcomes
Posted on March 19, 20253/19/25
Maximizing Sales with AI: A Strategic Roadmap for Success
Posted on December 6, 202312/6/23
Linking Channel Distribution & 3PL to Non-Traditional Commercialization Touchpoints
Posted on September 7, 20239/7/23
Balancing the Portfolio: How Extending Mature Brands’ Success Can Replenish Costs Invested In Launching New Products
Posted on September 7, 20239/7/23
Asset Optimization: Breathe New Life Into Mature Brands with EVERSANA REIGNITE™
Posted on August 21, 20238/21/23